ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Parkinson Disease Dementia, Dementia With Lewy Bodies

In brief

This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.

Key facts

Study ID

NCT04831281

Run by

LeonaBio

People needed

28

Starts

2022-01-20

Expected to finish

2023-04-19

Last updated by the study team

2025-03-04

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with confirmed diagnosis of Parkinson's disease or Dementia with Lewy Bodies
• MoCA score 11 to 23, inclusive, at screening
• Probable Parkinson's Disease Dementia or Lewy Body Dementia
• BMI between ≥ 16and ≤ 35 kg/m2 for females and between≥ 18 and ≤ 35 kg/m2 for males at Screening
• Reliable and capable support person/caregiver, who is willing to accept responsibility for supervising the treatment or, if required, administering study drug, and assessing the condition of the subject throughout the study in accordance with all protocol requirements

You may not qualify if…

• Hoehn-Yahr stage 5
• History of significant neurological disease other than PDD or DLB that may affect cognition at onset of dementia
• Subjects on deep brain stimulation
• History of brain MRI scan indicative of any other significant abnormality
• History of unexplained loss of consciousness, and epileptic fits
• Hearing test result considered unacceptable for auditory ERP P300 assessment
• Diagnosis of severe major depressive disorder even without psychotic features (GDS score [15-item scale] >7 at Screening)
• Significant suicide risk based on C-SSRS
• Significant psychosis (according to Diagnostic and Statistical Manual of Mental Disorders)
• Moderate or severe substance abuse disorder (according to DSM-5)
• Myocardial infarction or unstable angina within the last 6 months
• Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable)
• Clinically significant ECG abnormality at Screening
• Chronic kidney disease (eGFR < 45 mL/min using Cockcroft-Gault formula)
• Hepatic impairment with alanine aminotransferase or aspartate aminotransferase > 2 times the upper limit of normal, or Child-Pugh class B and C
• Malignant tumor within 3 years before Screening
• Memantine at any dose or combination
• Donepezil at 23 mg

Where it is running

• Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida, United States
• Premiere Research Institute — West Palm Beach, Florida, United States
• iResearch Atlanta, LLC — Decatur, Georgia, United States
• QUEST Research Institute — Farmington Hills, Michigan, United States
• Summit Research Network — Portland, Oregon, United States
• Center for Cognitive Health — Portland, Oregon, United States
• Keystone Clinical Studies LLC — Plymouth Meeting, Pennsylvania, United States
• Northwest Clinical Research Center — Bellevue, Washington, United States
• Evergreen Health Research — Kirkland, Washington, United States
• Inland Northwest Research LLC — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.